What EnColl Corporation does

EnColl Corporation is a privately held California corporation founded in 1994 that develops, manufactures, and markets Type-I collagen-based products across medical, dental, research, biotechnology, and consumer skincare applications. The company operates a proprietary Two-step enzyme Treatment Process (TTP) protected by three US patents (5,814,328; 6,127,143; 6,548,077), yielding 99% pure Type-I collagen with low immunogenicity, plus a patented phosphorylation modification that enhances bioactivity for soft and hard tissue regeneration. Its flagship product, Helicoll, is an FDA 510(k)-cleared bioengineered acellular skin substitute for wound management, with clinical use spanning thousands of cases over two decades.

The product portfolio is organized into five lines: dermal/surgical (Helicoll, Hemocoll, Surgicoll-Mesh), dental (OsseoGraft, OsseoMold, Healiguide, Periodontal Plus AB), research (CollagenPRO COAT cell-culture surfaces), biotechnology (Collatrix gene/drug delivery matrix), and skincare/nutrition (EncoSkin, NutriSale supplements). Revenue is generated through direct enterprise sales to hospitals, wound care centers, and specialty surgery practices; distributor channels including Sigma Chemicals (research products since 1999) and Vizient GPO (hospital access since 2019); licensing of patented collagen technologies to pharmaceutical and biotechnology partners; consulting and feasibility assessment services; and direct-to-consumer sales via helicoll.com. Research products are publicly priced at $39-$113 per package with case-volume discounts, while medical device pricing is not publicly disclosed.

EnColl is founder-led by Dr. S. Gunasekaran (PhD, biological-chemistry/neuro-physiology), who holds the three core patents and serves as CEO, with multiple Gunasekaran family members in operational leadership. The company employs 1-10 people, has no disclosed external funding rounds, no parent company, and no subsidiaries, operating as a lean specialty medical device and biomaterials firm pursuing niche applications in wound care, periodontal regeneration, orthopedics, and advanced therapy delivery.

Name

EnColl Corporation

Legal name

EnColl Corporation

Website

https://encoll.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

1–10 employees

Short description

EnColl Corporation is a privately held California medical device company founded in 1994 that develops and markets patented high-purity Type-I collagen products for wound care, dental surgery, research, gene therapy delivery, and skincare, sold to hospitals, specialty clinicians, and research labs.

Ownership category

akta.pro rank

Product category

Medical Devices (Collagen-based Biomaterials)

NAICS

Dental Equipment and Supplies Manufacturing (339114)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

akta.pro secondary industries

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Dermatology Specialty Pharmaceuticals (HLAIACAL), Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Collagen-based medical devices
• Wound care products
• Tissue regeneration biomaterials
• Dental bone grafts
• Gene therapy delivery

Headquarters

HQ city

Newark

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Sale of FDA-cleared collagen-based medical products including Helicoll (bioengineered skin substitute), dental products (OSSEOGRAFT, OSSEOMOLD, HEALIGUIDE, PERIODONTAL PLUS AB, HEMOCOLL, SURGICOLL-MESH), and dermal products for wound management, burns, and tissue regeneration.
2. Research Products: Sale of CollagenPRO COAT collagen-coated cell culture plates and research products to academic institutions, research laboratories, and biotech companies through distributors like Sigma Chemicals.
3. Licensing Royalties: Licensing of patented collagen technologies (patents 5,814,328, 6,127,143, 6,548,077) for pharmaceutical/biotechnology applications including drug delivery, stem cell treatments, and gene therapy.
4. Consulting and R&D Services: Feasibility assessment agreements and consulting services for pharmaceutical and medical device manufacturers evaluating collagen in their products, including pre-clinical tests, small animal studies, and histological analysis.
5. Nutritional Supplements: Sale of collagen-based nutritional supplements through NutriSale distribution for consumer health and wellness applications.
6. Cosmeceutical Products: Sale of EncoSkin collagen skincare cream for post-laser surgery, skin protection, and anti-aging applications.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels5 records

Core offering

EnColl Corporation develops, manufactures, and markets Type-I collagen-based products using a patented Two-step enzyme Treatment Process (TTP) that yields 99% pure collagen. Its portfolio spans FDA-cleared medical devices for wound management and dermal regeneration (Helicoll), surgical hemostats and bioresorbable matrices (Hemocoll, Surgicoll-Mesh), dental bone graft and periodontal products, collagen-coated cell culture research tools, gene/drug delivery gels (Collatrix), and collagen skincare.

Product overview

EnColl Corporation develops, manufactures, and markets Type-I collagen-based products using patented Two-step enzyme Treatment Process (TTP) technology that yields 99% pure collagen. The product portfolio includes: (1) Dermal/Surgical Products: Helicoll® (FDA-approved bioengineered skin substitute), Hemocoll™ (hemostat), and Surgicoll-Mesh™ (bioresorbable matrix); (2) Dental Products: OSSEOGRAFT and OSSEOMOLD (bone graft materials), HEALIGUIDE (periodontal membrane), PERIODONTAL PLUS AB (drug delivery), and Hemocoll for dental use; (3) Skincare: Enco Skin® collagen cream; (4) Research Products: CollagenPRO COAT (cell culture plates/flasks); (5) Biotechnology: Collatrix™ for gene/drug delivery. All products are manufactured in FDA/WHO-compliant facilities.

Differentiator

Problem solved

Functional benefit

Brands

• Helicoll®: Bioengineered high purity Type-I collagen forming an acellular skin substitute construct for wound management and tissue regeneration.
• Hemocoll™
• OsseoGraft
• OsseoMold
• Healiguide
• Periodontal Plus AB
• Surgicoll-Mesh™
• EncoSkin®
• CollagenPRO COAT
• Collatrix™

Products and services

• Helicoll FDA 510(k)-cleared bioengineered high-purity Type-I collagen (>97% pure) acellular skin substitute construct for wound management, burns, diabetic foot ulcers, and dermal regeneration in plastic surgery, dermatology, podiatry, and orthopedic surgery. Treatment course typically involves 1 to 4 applications.
• Hemocoll Absorbable sterile fibrillar collagen hemostat for bleeding wounds of trauma and surgery, including dental surgical applications.
• Surgicoll-Mesh Sterile, implantable, bioresorbable Type-I collagen matrix for tissue regeneration in surgical applications.
• OSSEOGRAFT Bone graft material made from high-purity Type-I collagen for bone void filling and augmentation in dental surgical procedures.
• OSSEOMOLD Moldable bone graft material for bone void filling and augmentation in dental surgical procedures.
• HEALIGUIDE Periodontal resorbable collagen membrane for guided tissue regeneration in dental applications.
• PERIODONTAL PLUS AB Periodontal infection treatment product providing local delivery of an approved anti-bacterial drug.
• EncoSkin (Enco Skin) Advanced Nanotech Type-I Collagen Topical Cream that reduces wrinkles and helps heal skin damage from laser and chemical treatments, radiation, photo-oxidation, and extreme temperatures; used as a post-laser surgery skin protectant.
• CollagenPRO COAT Patented thin collagen coating applied to cell culture vessels to enhance cell attachment and propagation. Available as collagen-coated multiwell plates (6, 12, 24, 48, 96, 384-well formats), petri dishes (35, 60, 100, 150mm), and tissue culture flasks (T-25, T-75, T-175). Distributed via Sigma Chemicals Inc.
• Collatrix DNA-infused gel of modified collagen used as a delivery matrix in gene therapy and for delivery of cytokines, growth factors, drugs such as insulin, and anti-microbial agents; claimed to offer greater biocompatibility and bioactivity than other available products.

Quantifiable outcome

• Early infiltration of new blood capillaries within 4-5 days after application
• +4 more outcomes

Named customers7 records

Segments1 record

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Vizient, Inc.coreGTM or Marketing Partner · 16 August 2019Awarded Innovative Technology contract for Helicoll biological skin substitute. Vizient is the largest member-driven healthcare performance improvement company in the US. The contract allows Vizient members enhanced savings for Helicoll and recognizes the product's next-generation technology for improving quality of care, reducing costs, and improving patient satisfaction.
• Sigma Chemicals Inc.coreChannel Partner/ Reseller/ Distributor · 1 January 1999One of the major US distributors for research products has tested and included EnColl's CollagenPRO COAT product in their catalogues since 1999. This partnership enables wide distribution of EnColl's research products to academic and commercial laboratories.
• Stanford University School of Medicine (Department of Dermatology)coreStrategic or Co-development PartnerClinical collaboration with Stanford EB clinic for treatment of Epidermolysis Bullosa patients using Helicoll. Discussions underway for participation in gene therapy EB clinical trials where patient skin cells treated with type VII collagen gene in retrovirus would be delivered via EnColl's bio-resorbable Helicoll Dressing.
• Major Life Science Products Distributor (Marketing Partner)minorChannel Partner/ Reseller/ DistributorAcademic and corporate collaboration includes marketing partnership with major life science products' distributor for collagen-based products.
• Pharmaceutical Companies (Feasibility Assessment)minorStrategic or Co-development PartnerEnColl involved in feasibility assessment agreements conducted with leading pharmaceutical and medical device manufacturers for evaluation of collagen in their products. Discussions are underway to discover and develop novel biomedical products.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• CollPlant Biotechnologies: Israel-based regenerative medicine company developing recombinant human Type-I collagen (rhCollagen) for tissue engineering, dermal fillers, and 3D bioprinting — an emerging technology alternative to EnColl's animal-derived purified collagen platform.

Direct peers

• Geistlich Pharma: Swiss dental and regenerative medicine company whose Bio-Oss and Bio-Gide collagen-based bone graft and membrane products directly compete with EnColl's OSSEOGRAFT, OSSEOMOLD, and HEALIGUIDE dental lines.
• LifeNet Health: Nonprofit tissue organization offering dermal allografts and regenerative wound care matrices, overlapping with Helicoll's bioengineered skin substitute use cases for chronic wound management.
• MTF Biologics: Nonprofit tissue bank producing allograft skin substitutes (e.g., AlloPatch) and wound care grafts, competing with Helicoll in advanced wound healing for hospitals and wound care centers.
• Organogenesis Holdings: Commercial-stage regenerative medicine company selling Apligraf and Dermagraft skin substitutes for chronic wounds and burns — direct head-to-head competitor to EnColl's Helicoll in bioengineered skin substitutes for wound management.
• Integra LifeSciences: Develops and markets regenerative skin substitutes (Integra Dermal Regeneration Template) and collagen-based wound care matrices, directly competing with Helicoll in advanced wound care and surgical tissue regeneration.
• MiMedx Group: Markets placental tissue allografts (EpiFix, AmnioFix) for wound healing and surgical recovery, directly competing with Helicoll in the diabetic foot ulcer and chronic wound treatment segments.

Broad incumbents

• Convatec Group: Established wound care, ostomy, and continence products company selling a broad portfolio of advanced wound dressings, overlapping with EnColl's wound management products across hospital channels.
• Smith & Nephew (Advanced Wound Management): Global medical device incumbent with a broad advanced wound care portfolio (e.g., PICO, ALLEVYN, Oasis) that overlaps with EnColl's wound healing and skin regeneration products, though not specialized in collagen skin substitutes.
• Coloplast: Global wound and skin care company with a broad advanced wound care portfolio (Biatain, Comfeel) addressing similar hospital and home-care customers as EnColl's wound healing products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/encoll-corp.

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EnColl Corporation